STCube, Inc. Information

STCube is a clinical-stage biotechnology company focused on the discovery and development of first-in-class cancer immunotherapies. The company is advancing novel immune checkpoint inhibitors, including programs targeting BTN1A1, to address patients who do not benefit from existing PD-1/PD-L1 therapies. Leveraging biomarker-driven development strategies, STCube is conducting multiple clinical studies to evaluate the safety and efficacy of its lead assets across solid tumors. The company aims to deliver innovative treatment options for patients with high unmet medical needs through strategic global partnerships and scientifically differentiated pipelines.